| Document |
Document Title |
|
WO/2017/051938A1 |
The present invention provides, by using a standard concentration-sensitivity graph and a protein analysis method in which a composite of an antibody-gene complex and an antigen and a marker material-secondary antibody complex is measure...
|
|
WO/2017/040965A1 |
A lubricant composition includes a base oil present in an amount of greater than 70 parts by weight per 100 parts by weight of the lubricant composition and an antioxidant. The antioxidant has the structure: wherein each X is independent...
|
|
WO/2017/029397A1 |
This invention provides a process for providing phosphoramidate derivatives, comprising performing a nucleophilic substitution reaction at phosphorous, where a phosphoryl chloride derivative is reacted with an oxime derivative to provide...
|
|
WO/2017/031156A1 |
Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymph...
|
|
WO/2016/197730A1 |
The present invention relates to an organic electroluminescent material, which has a structure as represented by formula (I). Compounds as represented by formula (I) have highly stable electron acceptor groups and electron donor groups, ...
|
|
WO/2016/179702A1 |
The invention relates to compositions useful in the treatment of a head and neck cancer, the composition comprising a therapeutically effective amount of an acridinone compound having the formula (I): or a pharmaceutically acceptable sal...
|
|
WO/2016/181844A1 |
In order to provide a π-conjugated compound that increases light-emission efficiency, this π-conjugated compound has: an absolute value for the difference between the lowest excited singlet energy level and the lowest excited triplet e...
|
|
WO/2016/176222A1 |
The present invention provides therapeutic strategies for treatment of severe debilitating diseases associated with IFN-I due to cGAS activation. In one aspect, the invention provides compounds of Formula (I): [Formula should be inserted...
|
|
WO/2016/173020A1 |
A conjugated compound containing a diphenyl sulfone phenyl structure, a method for preparing same, and use for fabricating a light emitting layer or an electronic transmission layer of an organic electroluminescent diode. The compound ha...
|
|
WO/2016/168540A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I):(I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A is a heterocyclic or h...
|
|
WO/2016/168721A1 |
The invention provides dimeric quinacrine derivatives and related compounds and compositions, methods of treatment and syntheses. The novel compounds exhibit unexpected anticancer activity and are useful in the treatment of a variety of ...
|
|
WO/2016/150799A1 |
We disclose novel asymmetric bis-acridines with antitumour activity. These compounds are useful for use in pharmaceuticals, particularly in the treatment or the prevention of neoplasms.
|
|
WO/2016/146655A1 |
The present invention relates to the compound having Formula (I) or pharmaceutically acceptable salts or solvates thereof, and its use in treating and/or preventing a Tauopathy.
|
|
WO/2016/116111A1 |
The present invention relates to a new class of substituted acridinium- and xanthenium-like fluorescent dyes having a 9-x-antracenium rings system. The new substituted fluorescent dyes may be attached to a linker, conjugated to carrier m...
|
|
WO/2016/111196A1 |
A compound represented by general formula (1) is useful as a host and an assist dopant. R1 to R5 independently represent a hydrogen atom or a substituent other than a cyano group, and at least one of R1 to R5 represents a group represent...
|
|
WO/2016/102412A1 |
Organic electronic device comprising an anode, a cathode and at least one emissive layer free of compounds of heavy atoms having an atomic number exceeding 40 comprising a compound of formula (1) wherein R1, is hydrogen, a C1-C18 alkyl g...
|
|
WO/2016/083915A1 |
The present invention relates to a 4-hydroxquinoline compounds of the formula (I) wherein A is selected from diradicals of the formulae (A.1), (A.2), (A.3), (A.4), (A.5), and (A.6) wherein R 1, R 2a, R 2b, R 3, if present R 4a, R 4b, R 5...
|
|
WO/2016/078738A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
|
|
WO/2016/064671A2 |
There is provided a compound having Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), or Formula (VI).
|
|
WO/2016/017757A1 |
The present invention addresses the problem of providing an organic electroluminescent element, etc. that makes it possible to suppress broadening of the absorption spectrum and light emission spectrum, improve light emission efficiency,...
|
|
WO/2016/005979A1 |
A method of increasing survival of viral infected honeybees, reducing viral load or protecting the honeybees from death, wherein said virus is a ssRNA virus, comprising administering to the honeybees an antiviral effective amount of an a...
|
|
WO/2015/199303A1 |
Provided are a compound represented by chemical formula I; an organic photoelectronic device comprising the same; and a display device comprising the organic photoelectronic device.
|
|
WO/2015/129714A1 |
A compound represented by general formula (1) is useful as a light-emitting material. R1, R3, and R5 represent fluorine atoms, or R1, R2, R4, and R5 represent fluorine atoms. The remaining R1-R6 represent groups represented by general fo...
|
|
WO/2015/109451A1 |
The present invention mainly pertains to catalytic processes for the direct amination of 2, -bis(hydroxymethyl) tetrahydrofuran to obtain compounds containing the 8-oxa-3-azabicyclo (3.2.1) octane ring, in the presence of: a homogenous c...
|
|
WO/2015/107119A1 |
The present invention relates to 4-azapodophyllotoxin analogs of formula (I) in which X, R1, R2, R3, R4 and Ar are as defined in claim 1, preferably a pharmaceutically acceptable salt thereof, optionally in the form of a solvate, a compo...
|
|
WO/2015/091308A1 |
The present invention relates to a compound obtainable by the condensation of a polyol having 3-4 hydroxyl groups, adicarboxylic acid or a derivative thereof, an alkanolamine anda fatty acid, followed by reaction with an alkylating agent...
|
|
WO/2015/080183A1 |
A compound represented by general formula (1) is useful as a light-emitting material. In general formula (1), zero to one of R1 to R5 represents a cyano group, one to five of R1 to R5 independently represent a group represented by genera...
|
|
WO/2015/068987A1 |
Provided are an organic compound represented by chemical formula 1 in the specification (see image in the specification) and an organic electroluminescent element comprising the same.
|
|
WO/2015/029354A1 |
[Problem] To provide a compound which emits fluorescence and delayed fluorescence as a material for a high efficiency organic electroluminescent element, and to further provide an organic photoluminescent element and a high efficiency, h...
|
|
WO/2015/006174A1 |
Hydrophilic, high quantum yield, chemiluminescent acridinium compounds with increased light output, improved stability, fast light emission and decreased non specific binding are disclosed. The chemiluminescent acridinium esters possess ...
|
|
WO/2014/206877A1 |
The compounds of formula (I), or its pharmaceutically acceptable salts, or any stereoisomer or mixture thereof, wherein: R1 and R1' are both H, or R1 and R1' are taken together forming a biradical of formula -CH2-C(R4)=CH-; R2 and R3 are...
|
|
WO/2014/203840A1 |
A compound represented by general formula (1) is a red light-emitting material that has a high luminous efficiency. R1 to R8 each represent a hydrogen atom or a substituent group, at least one from among R1 to R8 being a group represente...
|
|
WO/2014/180984A1 |
The present invention refers to compounds of formula (I): as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or chemoprevention of cancer hematological mal...
|
|
WO/2014/156184A1 |
[Problem] To provide: an organic photoelectric conversion element which has good response speed, carrier transport properties (sensitivity) and heat resistance; and an imaging element which is provided with this organic photoelectric con...
|
|
WO/2014/157238A1 |
The present invention addresses the problem of providing a photoelectric conversion material that excels in heat resistance and vapor-deposition stability, a photoelectric conversion element using the photoelectric conversion material, a...
|
|
WO/2014/157216A1 |
The present invention addresses the problem of providing a photoelectric conversion material well-suited for continuous evaporation, a photoelectric transducer in which the photoelectric conversion material is used, a method for using th...
|
|
WO/2014/146752A1 |
The present application relates to a compound of a formula (I) which comprises a benzene group that is substituted with a group selected from carbazole derivatives and bridged amines and with an electron attracting group, wherein the two...
|
|
WO/2014/123485A1 |
A method for the purification of a desired protein from a protein preparation includes conditioning the protein preparation by treatment with soluble organic multivalent ions, immobilized organic multivalent ions, or both, optionally in ...
|
|
WO/2014/104315A1 |
This electroluminescent element is characterized by comprising an anode, a cathode, and a light-emitting layer. The electroluminescent element is further characterized in that: the light-emitting layer contains a first compound and a sec...
|
|
WO/2014/051521A1 |
The present invention relates to methods and compositions for detecting an interaction between a protein and a ligand, comprising: (i) binding at least one fluorescent molecular rotor to said ligand or protein; and (ii) detecting a chang...
|
|
WO/2014/041125A1 |
The present invention relates to novel inhibitors of p21. These inhibitors are useful as therapeutic agents for promoting cell regeneration and in the treatment of cancer. Improvement of cell regeneration is particularly desirable in pat...
|
|
WO/2014/015935A2 |
The present invention concerns particular fluorenes, the use of the compound in an electronic device, and an electronic device containing at least one of these compounds. The present invention further concerns a method for producing the ...
|
|
WO/2014/017045A1 |
Provided are the following: an organic compound that, as a material for an organic electroluminescent element having high efficiency and high durability, has excellent positive hole injection/transport performance, has electron stopping ...
|
|
WO/2014/017042A1 |
[Problem] To manufacture, in a stable manner, an organic photoelectric conversion element having an equivalent performance, and an imaging element provided with the same. [Solution] A film-forming organic material (60) used for dry film-...
|
|
WO/2014/011762A1 |
A method is provided for N-alkylation of acridine compounds by reduction of acridines to corresponding acridans to improve the reactivity of the acridine nitrogen, and subsequent N-alkylation of the acridans in ionic liquid solvents to p...
|
|
WO/2013/182263A1 |
The invention relates to specific phenanthrenes, the use of the compound in an electronic device, and an electronic device containing at least one of said compounds. The invention further relates to a method for producing the compound an...
|
|
WO/2013/153780A1 |
[Problem] To provide an organic compound that, as a material for a high-efficiency, high-durability organic electroluminescent element, has superior hole injection/transport performance, has electron stopping ability, and has the charact...
|
|
WO/2013/102249A1 |
The present invention provided N-phenylpiperazine derivatives for use as multiple binders and/or antagonists of α1A adrenoceptors, α1D adrenoceptors and 5-HT1A serotonin receptors. These substances are candidates to prototypes for the ...
|
|
WO/2013/091052A1 |
The present invention relates to oncology, in particular to a molecular compound denominated here as "oncoloose", which is capable of selectively destroying solid tumour cells without affecting rapidly replicating healthy cells. The pres...
|
|
WO/2013/093019A1 |
The present invention relates to a compound of general formula (I) in which: - R1 and R2 are simultaneously or independently H, OH, OCH3 or a C1-C5 alkyl radical, - R3 and R4 are simultaneously CH3, - or R3 is H and R4 is CH3, CH2CH3 or ...
|
